Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03952039
Title An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene
Indications

myelofibrosis

Therapies

Fedratinib

Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.